Clinical Trials Directory

Trials / Conditions / Hodgkin Lymphoma, Adult

Hodgkin Lymphoma, Adult

18 registered clinical trials studyying Hodgkin Lymphoma, Adult — 6 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
NCT07021989
Michael Spinner, MDPhase 2
RecruitingNivo40-AVD for Advanced Classic Hodgkin Lymphoma
NCT06984146
National Medical Research Radiological Centre of the Ministry of Health of RussiaPhase 2
RecruitingCardiopulmonary Function and Cerebral Blood Flow in Hodgkin Lymphoma Survivors
NCT06421987
St. Jude Children's Research Hospital—
RecruitingSafety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
NCT05798897
Marker Therapeutics, Inc.Phase 1
UnknownPD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Cla
NCT05137886
Institute of Hematology & Blood Diseases Hospital, ChinaPhase 2
UnknownRWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT
NCT04776265
Grupo Argentino de Tratamiento de la Leucemia Aguda—
Active Not RecruitingPhase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CH
NCT04268706
Tessa TherapeuticsPhase 2
UnknownStudy of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal
NCT04758650
Universitair Ziekenhuis BrusselPhase 2
UnknownCAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.
NCT04653649
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauPhase 1 / Phase 2
RecruitingBREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant
NCT04378647
Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaPhase 2
RecruitingFirst Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)
NCT04638790
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of RussiaPhase 3
CompletedMolecular Imaging of Lymphoma Using Labeled Technetium-99m 1-Thio-D-Glucose
NCT04292626
Tomsk National Research Medical Center of the Russian Academy of SciencesPhase 1
UnknownNon-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study
NCT03260101
Cellect Biotechnology—
UnknownElderly Hodgkin Lymphoma Patients Treated With Chemoradiotherapy
NCT03535948
Central Hospital, Nancy, France—
UnknownPhysical Capacity in Hodgkin Lymphoma Survivors
NCT04636255
University of Sao Paulo General HospitalN/A
CompletedPD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma
NCT03155425
Jiangsu HengRui Medicine Co., Ltd.Phase 2
CompletedInduction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II
NCT01578967
UNC Lineberger Comprehensive Cancer CenterN/A
No Longer AvailableCompassionate Use Re-Infusion of ATLCAR.CD30
NCT03914885
UNC Lineberger Comprehensive Cancer Center—